IL-1RAP Inhibitor (ALM22307)

About Almirall

Almirall is a publicly traded, revenue-generating pharmaceutical company with a singular strategic focus on becoming a global leader in medical dermatology. The company has successfully transformed from a broad-based pharma player into a specialized dermatology entity, leveraging deep internal R&D, strategic partnerships, and a direct commercial infrastructure. Its mission is to deliver innovative science to improve the lives of patients with skin conditions, supported by a growing portfolio of marketed products and a promising clinical pipeline.

Therapeutic Areas